Activation of type 2 cannabinoid receptors (CB2R) promotes fatty acid oxidation through the SIRT1/PGC-1α pathway

Biochemical and Biophysical Research Communications

Volumn 436, Issue 3, 2013, Pages 377-381

  Zheng, Xuqin ^a   Sun, Tao ^b   Wang, Xiaodong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Fatty acid oxidation; Peroxisome proliferator activated receptor gamma coactivator 1 (PGC 1 ); Sirtuin 1 (Sirt1); Trans caryophyllene; Type 2 cannabinoid receptor (CB2R)

Indexed keywords

CANNABINOID 2 RECEPTOR; CARYOPHYLLENE DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SIRTUIN 1;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84879881379     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.05.108     Document Type: Article

References (25)

1. Wilson P.W. Diabetes mellitus and coronary heart disease. Endocrinol. Metab. Clin. North Am. 2001, 30:857-881.
2. Boden G., Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur. J. Clin. Invest. 2002, 32(Suppl 3):14-23.
3. Pyper S.R., Viswakarma N., Yu S., et al. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept. Signal. 2010, 8:e002.
4. Rodgers J.T., Lerin C., Haas W., et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
5. Gerhart-Hines Z., Dominy J.E., Blattler S.M., et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol. Cell 2011, 44:851-863.
6. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 1997, 74:129-180.
7. Cabral G.A., Griffin-Thomas L. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 11:e3.
8. Blazquez C., Casanova M.L., Planas A., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003, 17:529-531.
9. Van Sickle M.D., Duncan M., Kingsley P.J., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
10. Rajesh M., Mukhopadhyay P., Hasko G., et al. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br .J. Pharmacol. 2008, 153:347-357.
11. Gertsch J., Leonti M., Raduner S., et al. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. USA 2008, 105:9099-9104.
12. Choi I.Y., Ju C., Anthony Jalin A.M., et al. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am. J. Pathol. 2013, 182:928-939.
13. Gerhart-Hines Z., Rodgers J.T., Bare O., et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26:1913-1923.
14. Napper A.D., Hixon J., McDonagh T., et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 2005, 48:8045-8054.
15. Gerhart-Hines Z., Dominy J.E., Blättler S.M., et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+). Mol. Cell 2011, 44:851-863.
16. Sheng B., Wang X., Su B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
17. Wenz T., Rossi S.G., Rotundo R.L., et al. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. USA 2009, 106:20405-20410.
18. Bostrom P., Wu J., Jedrychowski M.P., et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012, 481:463-468.
19. Meeson A.P., Shi X., Alexander M.S., et al. Sox15 and Fhl3 transcriptionally coactivate Foxk1 and regulate myogenic progenitor cells. EMBO J. 2007, 26:1902-1912.
20. Fulco M., Schiltz R.L., Iezzi S., et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol. Cell 2003, 12:51-62.
21. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
22. Mendez-Sanchez N., Zamora-Valdes D., Pichardo-Bahena R., et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int. 2007, 27:215-219.
23. Mestre L., Correa F., Docagne F., et al. The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem. Pharmacol. 2006, 72:869-880.
24. Lipina C., Stretton C., Hastings S., et al. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 2010, 59:375-385.
25. Montecucco F., Lenglet S., Braunersreuther V., et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J. Mol. Cell. Cardiol. 2009, 46:612-620.